Olmesartan Tad (Olmesartan Medoxomil)

Olmesartan Tad is an angiotensin II receptor blocker indicated for conditions affecting the renin‑angiotensin system.

• Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk.
• Heart failure: used as part of combination therapy to improve symptoms and outcomes.
• Diabetic nephropathy: helps slow progression of kidney damage associated with diabetes.
• Post‑myocardial infarction: contributes to blood‑pressure control in patients after a heart attack.
• Chronic kidney disease: assists in managing elevated blood pressure in CKD patients.
• High‑risk vascular risk patients: aids in overall vascular risk reduction.

• Olmesartan medoxil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and lower systemic blood pressure.

Olmesartan Tad may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Cough

Serious or Rare Side Effects

• Angio‑angry  
• Hyper‑hyper  
• Severe hypotension
• Acute kidney injury
• Liver enzyme elevation
• Anaphylaxis  

Olmesartan Tad should be used with caution in specific clinical situations.

• Renal impairment: adjust dosing and monitor kidney function.
• Hepatic impairment: use with caution; limited data in severe liver disease.
• Electrolyte disturbances: monitor serum potassium and sodium levels.
• Pregnancy  
• Breastfeeding  
• Store at ambient  :  keep   

• The     
• ---
•   
•   
•     
•     
• t  
• t \\